 phase intraven infus new deriv camptothecin treatment advanc non-small-cel lung cancer carbonyloxy-camptothecin novel camptothecin deriv clinic evalu broad spectrum antitumor activ anim model uniqu inhibitori effect mammalian dna topoisomeras seventeen patient advanc non-small-cel lung cancer weekli dose level weekli dose patient total weekli dose patient dose-limit toxic effect myelosuppress unpredict diarrhea gastrointestin toxic effect sever standard therapi patient interpati variabl toxic effect substanti death pharmacokinet paramet major metabolit untreat patient dose partial respons month maximum toler dose schedul start dose phase II studi schedul dose intens doubl dose intens possibl once-a-month schedul care supervis gastrointestin toxic effect myelosuppress indispens wide individu differ drug toler